证券代码：603811 证券简称：诚意药业 公告编号：2025-012 浙江诚意药业股份有限公司 2024 年度主要经营数据的公告 根据上海证券交易所发布的《上市公司行业信息披露指引第六号——医药制造》的 要求，现将浙江诚意药业股份有限公司（以下简称"公司"）2024 年度主要经营数据披 露如下： 一、报告期内，公司主营业务分行业、分产品经营情况： 单位：元 币种：人民币 | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率（%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比上 | | | | | | 减（%） | 减（%） | 年增减（%） | | 医药制造业 | 712,308,635.02 | 215,861,814.09 | 69.70 | 6.38 | -9.59 | 5.35 | | | | 主营业务分产品情况 | | | | | | 分产品 | 营业收入 | 营业成本 | 毛利率（%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率 ...

证券代码：000623 证券简称：吉林敖东 吉林敖东药业集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | | --- | --- | --- | | 投资者关系活 | | | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 及人员姓名 | 参与本次 2024 年度业绩说明会的投资者 | | | 时间 | 2025 年 4 28 日（星期一）15:00—17:00 | 月 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 副董事长、总经理：郭淑芹 | | | | 独立董事：肖维维 | | | 人员姓名 | 董事、副总经理、财务总监：张淑媛 | | | | 董事、副总经理、董事会秘书：王振宇 | | | | 1、行业以后 ...

4月27日，记者从南京市统计局、国家统计局南京调查队了解到，一季度全市经济延续回升向好态 势，经济运行起步平稳、稳中有进。根据地区生产总值统一核算结果，一季度全市实现地区生产总值 4718.70亿元，按不变价格计算，同比增长5.3%。其中，第一产业增加值46.69亿元，同比增长3.7%； 第二产业增加值1417.95亿元，增长4.2%；第三产业增加值3254.06亿元，增长5.8%。 一季度，全市农业生产形势稳定，畜牧蔬果稳定增长。全市农林牧渔业增加值57.70亿元，可比增 长4.1%。春耕备耕有序推进，夏粮面积稳中有增。主要畜禽监测调查数据显示，一季度末，全市生猪 存栏22.75万头，同比增长3.9%；全市生猪出栏10.27万头，同比增长0.5%。一季度，全市蔬菜播种面 积23.86万亩，总产量54.49万吨，与上年总体持平。水果产量2.12万吨，同比增长12.2%。 工业生产稳中有进，制造业保持较快增长。一季度，全市规模以上工业增加值同比增长6.4%，增 速较1—2月提升0.4个百分点，较去年全年提升3.2个百分点。分行业看，全市规模以上工业37个行业 大类中，30个行业增加值保持同比增长，整体行业增长面 ...

GDP同比增长5.3%，一季度南京市经济运行起步平稳、稳中有进—— 透过三项数据感受发展"脉动" □ 南京日报/紫金山新闻记者 张甜甜 王健 通讯员 林娜 南京市统计局、国家统计局南京调查队，4月27日发布一季度南京经济运行数据：一季度全市实现地区 生产总值4718.70亿元，按不变价格计算，同比增长5.3%。记者注意到，宏观大数据背后，高技术制造 业、互联网和相关服务业、社会消费品零售总额增加值等指标表现突出。 这些数据意味着什么？数据背后，企业和市民"体感"如何？连日来，记者进社区、访工厂、看产线、走 市场，"翻阅"企业"运营账本"、个人"家庭账本"，触摸产业向上攀升的蓬勃脉动，感受经济起步平稳、 稳中有进的良好势头。 【数据】 统计数据显示，我市规模以上制造业增加值同比增长7.1%，较1—2月提升0.5个百分点，其中电气机械 和器材制造业、仪器仪表制造业、专用设备制造业、医药制造业等重点行业分别增长12.5%、21.2%、 12.2%和13.7%。规模以上高技术制造业增加值同比增长10%，较去年同期和去年全年分别提升8.6个、 9.1个百分点。 【镜头】 在巴基斯坦西北边境莫赫曼德地区，Mohmand水 ...

Group 1 - Renowned private equity firm Zhengyuan Investment recently conducted research on five listed companies [1][2][3] - Kuaihua Pharmaceutical signed a cooperation intention letter with Peking University Medical Department to establish a joint laboratory for enzyme sources and innovative drugs in 2024 [1] - Qingda Environmental Protection provides energy-saving and environmental protection solutions for various industries including power, chemicals, and waste treatment [1] - Zhongjian Technology invested in 1X Holding AS, entering the artificial intelligence robotics sector [2] - Jinyang Co., Ltd. reported a main revenue of 324 million yuan in Q1 2025, a year-on-year increase of 26.59%, but a net profit decline of 14.49% [2] - Dongsheng Technology holds a 2.54% stake in Bluestar Wisdom, involved in battery recycling and utilization, and is a leader in lithium battery cathode materials [3] Group 2 - Zhengyuan Investment was established in 2015 in Shenzhen Qianhai Free Trade Zone and has a private securities investment fund license [4] - The firm focuses on China's economic transformation and aims to connect social capital with quality industries, enhancing asset value for clients [4]

Operating Overview - The total operating revenue of ST Longjin (002750) for 2024 was 66.48 million yuan, a year-on-year decrease of 23.25% [2] - The net profit attributable to shareholders was -41.44 million yuan, an increase of 41.58% year-on-year; the net profit after deducting non-recurring gains and losses was -50.46 million yuan, up 37.78% year-on-year [2] - Despite poor annual performance, the fourth quarter showed improvement with total operating revenue of 19.87 million yuan, a year-on-year increase of 27.65% [2] Profitability Analysis - The company's profitability improved in 2024, with a gross margin of 64.25%, an increase of 5.53% year-on-year [3] - The net profit margin was -70.66%, an increase of 27.36% year-on-year, indicating that the company remains in a loss position [3] Cost and Expense Analysis - Total sales, management, and financial expenses amounted to 66.58 million yuan, accounting for 100.15% of revenue, a decrease of 7.73% year-on-year [4] - The reduction in sales expenses was primarily due to the implementation of centralized procurement price linkage policies in non-centralized procurement provinces [4] Cash Flow Situation - The operating cash flow per share was -0.09 yuan, an increase of 12.8% year-on-year, indicating some improvement [5] - However, the average operating cash flow over the past three years relative to current liabilities was -78.8%, suggesting ongoing concerns regarding cash flow [5] Asset and Liability Situation - The company's cash and cash equivalents amounted to 262 million yuan, a year-on-year increase of 24.2%, indicating a healthy cash position [6] - Accounts receivable decreased by 27.86% year-on-year to 8.75 million yuan, reflecting improved collection [6] Development Prospects and Risks - The company has been deeply involved in the pharmaceutical manufacturing industry for many years, holding nearly 40 domestic and foreign invention patents [7] - However, the product structure remains single, with revenues from other chemical generic drugs being relatively small [7] - The company faces multiple risks, including industry policy changes, research and development innovation, management, and safety and environmental protection [7] Summary - Overall, ST Longjin showed some recovery in profitability in 2024, but the overall operating condition remains under significant pressure [8] - The company needs to further optimize its product structure, enhance market competitiveness, and strengthen cash flow management and risk prevention for sustainable development [8]

Core Viewpoint - Iwubio has demonstrated steady growth in its financial performance, with a focus on innovation in the desensitization treatment sector, positioning itself as a leader in a competitive market [1] Group 1: Financial Performance - For the year 2024, Iwubio reported a revenue of 925 million yuan, representing a year-on-year growth of 9.10% [1] - The net profit attributable to shareholders was 318 million yuan, an increase of 2.46% year-on-year [1] - In Q1 2025, the company achieved a revenue of 228 million yuan, up 5.7% year-on-year, with a net profit of 74 million yuan, reflecting a growth of 1.5% [1] - Operating cash flow for Q1 2025 reached 85.88 million yuan, marking a significant increase of 96.2% [1] - Cumulatively, the company has distributed over 850 million yuan in cash dividends since its listing, which is approximately four times the amount raised during its IPO [1] Group 2: Competitive Advantages - Iwubio has established three competitive barriers: technological innovation, product scarcity, and industry leadership [2][3][4] - The company invested 125 million yuan in R&D in 2024, accounting for 13.48% of its revenue, which is above the industry average [2] - Iwubio's product "Dust Mite Drops" is the only sublingual desensitization treatment available in China, providing a significant advantage in terms of safety and convenience compared to subcutaneous alternatives [3] - The market share of Iwubio's "Dust Mite Drops" has consistently remained above 81.72%, confirming its leading position in the domestic desensitization treatment market [4] Group 3: Growth Potential - The allergy treatment market is expected to grow due to the increasing prevalence of allergic diseases, with reports indicating that around 40% of the Chinese population suffers from such conditions [5] - Iwubio's "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" have shown significant growth, with the latter achieving a 76.43% increase in 2024 [5] - The company is expanding its product offerings in the allergy testing market, with new products like "Pollen Skin Prick Test Solutions" receiving market approval [5] - Iwubio is also venturing into stem cell therapies and natural medicines, aiming to create a second growth curve [6] - The company has identified a drug molecule for antibiotic-resistant tuberculosis and is advancing its clinical research [6] Group 4: Strategic Outlook - Iwubio's strategic positioning in the allergy treatment sector, combined with its innovative approaches in stem cell and natural medicine, suggests a robust growth trajectory [7] - The company is well-positioned to navigate the evolving pharmaceutical landscape, focusing on both maintaining its core allergy treatment business and exploring new therapeutic areas [7]

Company Overview - The company is an innovative drug development enterprise focused on the research and commercialization of new drugs, with all products being independently developed and holding global intellectual property rights [8] - The company has established a comprehensive research and development system covering the entire drug development process, including drug chemistry, pharmacology, clinical research, and regulatory affairs [22] Financial Performance - In 2024, the company reported a net loss attributable to shareholders of 240.20 million yuan, with a cumulative unremedied loss of 2.54492 billion yuan [7] - The company does not plan to distribute cash dividends or issue bonus shares for the 2024 fiscal year [7] Product Pipeline - The company has two authorized products, Beifu Tini and Gesorese, which have been approved for market entry, while other products are still in clinical development [6][9] - Beifu Tini is a third-generation EGFR tyrosine kinase inhibitor for treating EGFR mutation-positive non-small cell lung cancer, with its second-line indication approved in 2023 and included in the National Medical Insurance Directory [9][10] - Gesorese is a KRAS G12C inhibitor for treating various cancers, with its NDA accepted in December 2023 and approved in November 2024 [11][12] Market Overview - The global pharmaceutical market has shown stable growth, increasing from $1,266.7 billion in 2018 to $1,495 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% [33] - The Chinese pharmaceutical market is expected to grow at a CAGR of 8.1% from 2022 to 2025, reaching 196.27 billion yuan by 2025 [33] - The global oncology drug market has grown from $110.6 billion in 2017 to $181.7 billion in 2021, with a CAGR of 13.2%, and is projected to reach $484.5 billion by 2030 [36] Clinical Trials and Research - The company is conducting multiple clinical trials for its products, including ongoing phase III trials for Taragarestrant and D-0120, which are aimed at treating breast cancer and hyperuricemia, respectively [17][19] - D-2570, a selective TYK2 inhibitor for treating psoriasis, has shown promising results in clinical trials and is expected to provide a new treatment option for autoimmune diseases [20] Competitive Landscape - The company faces competition from established pharmaceutical firms with stronger financial resources and market experience, which may impact its ability to commercialize its products effectively [5] - The innovative drug development industry is characterized by high investment, long cycles, and significant risks, with many products facing uncertainty in their development and market acceptance [4][5]

Company Performance - Guangyuyuan achieved an operating income of 1.22 billion yuan and a net profit attributable to shareholders of 74.45 million yuan for the year 2024 [1] - In Q1 2025, the company reported an operating income of 417 million yuan, a year-on-year increase of 21.48%, and a net profit of 63.58 million yuan, up 53.94% year-on-year [1] Industry Overview - The pharmaceutical manufacturing industry in China has shown signs of transformation driven by policy changes and market demand, with total operating income for 2024 at 25,298.5 billion yuan, remaining stable compared to 2023 [2] - The total profit for the pharmaceutical manufacturing industry in 2024 was 342.07 billion yuan, reflecting a year-on-year decline of 1.1%, although the rate of decline has slowed [2] - The traditional Chinese medicine sector is recovering growth due to government support and external factors such as an aging population and increased health demands [2] R&D and Innovation - Guangyuyuan has a history of 484 years and is recognized as a "Chinese Time-honored Brand," with key products included in national and provincial intangible cultural heritage lists [3] - The company increased its R&D expenditure to 38.59 million yuan in 2024, a 22.98% increase from the previous year, focusing on key products to enhance competitiveness [3] - Guangyuyuan is committed to a dual-driven development model of inheritance and innovation, collaborating with research institutions to create profitable research outcomes [3] Marketing Strategy - There is a growing demand for traditional Chinese medicine for health maintenance, with Guangyuyuan's products targeting specific consumer groups, indicating potential growth in the outpatient market [4] - The company has deepened strategic partnerships with top-tier chains and expanded its marketing channels, leading to significant growth in sales revenue [4] - Guangyuyuan has established a digital economy division to enhance online sales channels, adapting to new consumer trends and creating a strong competitive advantage [4]

第一季度财务报表是否经审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688091 证券简称：上海谊众 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...